Volume | 688,510 |
|
|||||
News | - | ||||||
Day High | 84.92 | Low High |
|||||
Day Low | 84.11 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
84.50 | 84.11 | 84.92 | 84.13 | 84.98 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,046 | 688,510 | $ 84.59 | $ 58,244,129 | - | 65.572 - 88.2312 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 25,075 | $ 84.13 | USD |
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
42.04B | 499.70M | - | 9.46B | 974M | 1.95 | 43.16 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alcon News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 87.70 | 88.2312 | 84.11 | 86.74 | 1,246,894 | -3.57 | -4.07% |
1 Month | 78.11 | 88.2312 | 77.72 | 84.56 | 1,141,180 | 6.02 | 7.71% |
3 Months | 77.00 | 88.2312 | 74.30 | 80.28 | 905,527 | 7.13 | 9.26% |
6 Months | 81.23 | 88.2312 | 69.44 | 76.92 | 868,862 | 2.90 | 3.57% |
1 Year | 66.55 | 88.2312 | 65.572 | 76.77 | 891,702 | 17.58 | 26.42% |
3 Years | 68.28 | 88.78 | 55.21 | 73.90 | 854,261 | 15.85 | 23.21% |
5 Years | 56.97 | 88.78 | 39.37 | 66.71 | 1,007,722 | 27.16 | 47.67% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |